Glenmark Pharmaceuticals Limited — Investor Meet, 26-05-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Glenmark Pharmaceuticals reported steady revenue growth and improved profitability in Q4 FY 2024-25, driven by robust product launches and cost controls. Management highlighted focus on expanding key markets, enhancing R&D productivity, and improving margin profile through operational efficiencies. They remain confident about sustained growth amid competitive dynamics and see strong execution momentum ahead. Analyst queries on innovation pipeline and margin sustainability were addressed positively, underscoring a forward-looking approach to value creation.